Target intelligence / Profile preview

Dual specificity phosphatase 22 (DUSP22)

Target
DUSP22
Molecular classification
Enzyme, Dual specificity phosphatase, Protein tyrosine phosphatase, Mitogen-activated protein kinase phosphatase
01

Overview

Dual specificity phosphatase 22 (DUSP22) is an enzyme belonging to the dual specificity phosphatase family, capable of dephosphorylating both tyrosine and serine/threonine residues on substrate proteins. DUSP22 plays a regulatory role in multiple cell signaling pathways, most notably inhibiting the mitogen-activated protein kinase (MAPK) signaling cascades including ERK, JNK, and p38 pathways. DUSP22 is implicated in the negative regulation of T-cell receptor and B-cell receptor signaling, immune responses, and modulation of cell transcription and adhesion. It acts in both cytoplasmic and nuclear compartments, influencing degradation of proteins such as the E3 ubiquitin ligase UBR2 and inactivating kinases like LCK. DUSP22 is associated with a variety of diseases, particularly cancers (hematologic and leukemia), immune system disorders, and kidney diseases. Despite its therapeutic relevance as a regulatory phosphatase, no specific drugs are in clinical use that target DUSP22 directly.

Other names
MKPXJSP1JKAPVHXLow molecular weight dual specificity phosphatase 2Mitogen-activated protein kinase phosphatase XDual specificity protein phosphatase 22JNK pathway associated phosphataseJNK-stimulatory phosphatase-1
02

Mechanism of action

Inhibition of MAP kinase pathways (ERK, JNK, p38) via dephosphorylation; Inhibition of T-cell receptor and B-cell receptor signaling; Promotion of degradation of E3 ubiquitin ligase UBR2; Inactivation of tyrosine kinase LCK

03

Biological functions

Dephosphorylation of phosphotyrosine and phosphoserine/threonine residuesNegative regulation of T-cell receptor signaling pathwayNegative regulation of focal adhesion assemblyRegulation of B-cell receptor signalingNegative regulation of transcription by RNA polymerase IISignal transduction
04

Disease associations

CancerHematologic cancerLeukemia (acute myeloid)Immune system disordersKidney diseases (including diabetic nephropathy, hypertensive nephropathy, lupus nephritis, chronic kidney disease, acute kidney injury)
05

Safety considerations

Potential for dysregulation leading to cancer or immune dysfunctionLimited clinical translation data due to off-target or systemic effects in MAPK pathway targeting

Beyond the preview

Go deeper on Dual specificity phosphatase 22 (DUSP22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual specificity phosphatase 22 (DUSP22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call